Salinomycin inhibits osteosarcoma by targeting its tumor stem cells

Area of Science:

• Oncology
• Cancer Stem Cell Biology

Background:

• Osteosarcoma is a common pediatric bone cancer with a poor prognosis.
• Osteosarcoma stem cells (TSCs) are implicated in tumor initiation, relapse, and metastasis.
• Current treatments often fail to eradicate TSCs, contributing to poor outcomes.

Purpose of the Study:

• To enrich osteosarcoma stem cells (TSCs) using multiple methods.
• To evaluate the efficacy of salinomycin in selectively targeting TSCs.
• To investigate the underlying mechanisms of salinomycin's action.

Main Methods:

• Enrichment of TSCs via sarcosphere formation, chemotherapy selection, and stem cell marker (OCT4, SOX2) overexpression.
• In vitro and in vivo assessment of salinomycin's effect on osteosarcoma and TSCs.
• Analysis of the Wnt/β-catenin signaling pathway.

Main Results:

• Sarcosphere selection, chemotherapy, and marker overexpression successfully enriched TSCs.
• Salinomycin demonstrated selective inhibition of osteosarcoma stem cells in vitro and in vivo.
• Salinomycin treatment showed minimal side effects.
• The Wnt/β-catenin signaling pathway appears to be involved in salinomycin's inhibitory effects.

Conclusions:

• Salinomycin is a potent inhibitor of osteosarcoma stem cells.
• Targeting TSCs with salinomycin offers a promising therapeutic strategy for osteosarcoma.
• Further clinical evaluation of salinomycin for osteosarcoma treatment is warranted.